Abstract: Background and Objective: Acute and chronic gastritis both possess dyspeptic symptoms. The objective of present study was to explore the effect of zerumbone on the acute or chronic gastritis. Materials and Methods: The study was divided into three different groups of 220 patients each. Zerumbone with hydroxypropyl-β-cyclodextrin the inclusion complex was prepared by the freeze-drying method. All patients of vehicle group, treatment group and control group were injected with 2 mL Water For Injection (WFI), 2 mL solution containing 20 μM doses of zerumbone and 0.15 g ranitidine capsule taken orally, respectively for 20 days. All patients were analyzed by gastric endoscopic examination. The biopsies of gastric tissue were made to perform the histopathological study and urea breath tests. The one-way ANOVA/the Dunnett’s multiple comparison tests were used for significant difference of scores at 95% level of confidence. Results: Zerumbone treatment was prevented epigastric pain, nausea, anorexia, vomiting and inflammation of gastric mucosa after 20 days of treatment (p≤0.05 for all parameters). Numbers of patients with infection of Helicobacter pylori were 22 and 2 (p≤0.05) for before and after zerumbone treatment. Conclusion: Zerumbone treatment was quite effective and safe in acute and chronic gastritis with or without Helicobacter pylori infection Clin.